For Shire, Life After Adderall XR? Yes

Shire has scaled its Adderall XR patent cliff, replenishing lost blockbuster sales with revenues from niche products, smart life-cycle management, and some good-old-fashioned luck. IN VIVO interviews CEO Angus Russell.

Jessica Merrill

With the loss of its top-selling drug – the attention deficit/hyperactivity drug Adderall XR (amphetamine extended release) – to generic...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo